Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (9602)	2/29/2008 10:37:18 AM
From: Ben Antanaitis	Respond to of 10345

And a little about this morning's downturn (the ads will appear shortly on your local cable channels): Mark & Associates, P.C. & MacDonald Rothweiler Eisenberg L.L.P. to Evaluate Claims Involving Tysabri Patients Diagnosed With Severe Liver Damage or Melanoma PrimeNewswire - February 29, 2008 9:32 AM ET Related Quotes Symbol Last Chg BIIB Trade 58.28 -2.30 ELN Trade 22.97 -0.55 Mark & Associates, P.C. & MacDonald Rothweiler Eisenberg L.L.P. announced that they are evaluating claims of patients treated with the drug Tysabri(r) who have been diagnosed with severe liver damage or melanoma. The announcement comes shortly after the manufacturers of Tysabri, Biogen Idec Inc. (Nasdaq:BIIB) and Elan Corp. plc (NYSE:ELN), warned about reports of liver toxicity in patients treated with the drug following its approval by the Food and Drug Administration, and a letter in the New England Journal of Medicine cautioned doctors about two aggressive cases of malignant melanoma that occurred shortly after the drug was administered. Tysabri(r) patients who have been diagnosed with severe cases of liver damage or melanoma are encouraged to visit youhaverights.com for a free legal consultation. The letter sent to healthcare professionals warning about the risk of liver damage in patients treated with Tysabri(r) is available on the FDA website at fda.gov. An extract of the letter that appeared in the New England Journal of Medicine is available on the NEJM website at content.nejm.org. About Tysabri(r) Tysabri(r), the brand name for natalizumab, is a monoclonal antibody that is approved for the treatment of Multiple Sclerosis (MS) and Crohn's disease. Tysabri(r) was first approved by the FDA in November 2004, but was removed from the market just three months later after several patients were diagnosed with a rare, often fatal opportunistic brain infection called progressive multifocal leukoencephalopathy (PML). The FDA allowed Tysabri back on the market in June 2006 for the treatment of Multiple Sclerosis with revised warnings and strict requirements for close monitoring of patients receiving the drug. Earlier this year, the FDA approved Tysabri for the treatment of Crohn's disease. Tysabri(r) Litigation Experience The attorneys at Mark & Associates, P.C. & MacDonald Rothweiler Eisenberg L.L.P. have a track record of both past and present litigation against Biogen Idec and Elan on behalf of Tysabri(r) victims. The firms currently represent the family of a patient who died from an opportunistic infection after receiving Tysabri(r). The case is pending in the U.S. District Court in Boston, Massachusetts (Civil Action No. 07-CA-11840 (DPW)). In 2006, in a highly publicized case, the attorneys at the firms represented the family of a woman who died from PML following Tysabri(r) treatment in state court in Massachusetts. See www.fda.gov/ohrms/dockets/AC/06/slides/2006-4208OPH1-01-MacDonald.ppt; news-service.stanford.edu. About Mark & Associates, P.C. Mark & Associates, P.C. is a leading products liability and personal injury law firm with offices in Boston, Massachusetts and Long Island, New York. The firm aggressively represents victims of defective pharmaceuticals and medical devices, dangerous consumer products, bad faith insurance denials, toxic exposure and serious auto and common carrier accidents. About MacDonald Rothweiler Eisenberg L.L.P. MacDonald Rothweiler Eisenberg L.L.P. is a leading plaintiff's law firm with a national practice, regarded for its accomplishments in litigation involving pharmaceutical products, personal injury, mass tort, medical malpractice, automobile "crashworthiness" and complex product liability. The firm's trial lawyers have over 100 years of combined experience, and have achieved record-breaking results for its clients in cases against Fortune 500 companies and large insurance companies. MacDonald Rothweiler Eisenberg L.L.P. has offices in Boston, Massachusetts, Philadelphia, Pennsylvania and Cherry Hill, New Jersey. This news release was distributed by PrimeNewswire, www.primenewswire.com SOURCE: Mark & Associates, P.C. Mark & Associates, P.C. Jason Mark, Esq. 1-866-507-4448 info@youhaverights.com Ben..... you don't have to like the news, but you must be aware of the news.

To: fred hayes who wrote (9602)	3/1/2008 11:09:22 PM
From: IRWIN JAMES FRANKEL	Read Replies (5) \| Respond to of 10345

A few comments on Tysabri: I went in with my wife to see her neuro. My wife will be starting on T soon. Here are a few of the items that came out: - the local infusion center is seeing about 15% of patients develop anti-bodies to T, most by the second infusion, the rest by the 3rd - no patient has developed antibody reactions after the 3rd infusion - this center discontinues T in patients who react to treatments and do not use antihistamines to try and continue T treatment - most patients receiving T are very happy with the results - the center will be adding regular blood panels to monitor liver enzymes - there are still no available assays for PML and thus the regular survey questions and MRI's when suspect - PML can be read on MRI's and distinguished from MS lesions - they scoffed at the suggestion that T caused melanoma - the Center has not used Rituxan - they are excited about new treatments advancing that will change the management of MS ij